Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada.
Oral Oncol. 2013 Jan;49(1):79-85. doi: 10.1016/j.oraloncology.2012.07.015. Epub 2012 Aug 20.
To describe the natural course of distant metastases (DMs) following radiotherapy (RT) or chemoradiotherapy (CRT) in HPV(+) oropharyngeal carcinoma (OPC).
OPC treated with RT/CRT from 1/1/2000 to 5/31/2010 were reviewed. The natural course of DM were compared between HPV(+) and HPV(-) cohorts.
Median follow-up was 3.9 years. The DM rate were similar (11% vs. 15% at 3-years, p=0.25) between the HPV(+) (n=457) vs. the HPV(-) (n=167) cases. While almost all (24/25) HPV(-) DM occurred within 2-years following RT (1 was at 2.1 years), 7/54 (13%) of HPV(+) DM were detected beyond 3 years (up to 5.3 years). Disseminating to >2 organs occurred in 18 (33%) HPV(+) vs. none in HPV(-). Post-DM survival rates were 11% vs. 4% at 2-years (p=0.02) for the HPV(+) vs. HPV(-) cases respectively. 5/6 HPV(+) with lung oligo-metastasis were still alive with stable disease beyond 2-years after salvage procedures for DM (chemotherapy: 3; surgical resection: 2; radiotherapy: 1).
Although DM rates are similar, the natural course of HPV(+) DM differs from that of HPV(-) patients: it may occur after a longer interval, often with a "disseminating" phenotype, and a small number may have prolonged survival after salvage for DM.
描述 HPV(+)口咽癌(OPC)患者在接受放疗(RT)或放化疗(CRT)后远处转移(DM)的自然病程。
回顾了 2000 年 1 月 1 日至 2010 年 5 月 31 日接受 RT/CRT 治疗的 OPC 患者。比较了 HPV(+)和 HPV(-)两组患者的 DM 自然病程。
中位随访时间为 3.9 年。HPV(+)组(n=457)和 HPV(-)组(n=167)的 DM 发生率相似(3 年时分别为 11%和 15%,p=0.25)。尽管几乎所有(24/25)HPV(-)DM 都发生在 RT 后 2 年内(1 例发生在 2.1 年),但 7/54(13%)HPV(+)DM 发生在 3 年后(最长至 5.3 年)。18 例(33%)HPV(+)DM 扩散至>2 个器官,而 HPV(-)中无此情况。HPV(+)组和 HPV(-)组患者 2 年时的 DM 后生存率分别为 11%和 4%(p=0.02)。6 例 HPV(+)肺寡转移患者在 DM 挽救治疗(化疗:3 例;手术切除:2 例;放疗:1 例)后 2 年以上仍存活且疾病稳定。
尽管 DM 发生率相似,但 HPV(+)DM 的自然病程与 HPV(-)患者不同:它可能发生在更长的时间间隔后,通常表现为“播散”表型,少数患者在 DM 挽救治疗后可能有较长的生存时间。